Clinical trial
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable…
NCT00021047 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00021047 |
|---|---|
| Title | Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor |
| Official title | A Phase I/II Trial of Epirubicin, Carboplatin & Capecitabine in Adult Cancer Patients |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | capecitabine, carboplatin, epirubicin hydrochloride |
| Start date | Jul 1, 2001 |
| Completion | Jun 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 8, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: